Pharmacokinetics of ondansetron in patients with hepatic insufficiency

Journal of Clinical Pharmacology

Volumn 36, Issue 3, 1996, Pages 206-215

  Figg, William D ^a,d   Dukes, George E ^a   Pritchard, J Fred ^c   Hermann, David J ^c   Lesesne, Henry R ^b   Carson, Stanley W ^a   Songer, Stephen S ^a,e   Powell, J Robert ^c   Hak, Lawrence J ^a,f  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c GLAXOSMITHKLINE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e Marion Merrell Dow Inc   (United States)

^f UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BILIRUBIN; CYTOCHROME P450; INDOCYANINE GREEN; ONDANSETRON; PHENAZONE; PLASMA PROTEIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG METABOLISM; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER FAILURE; LIVER FUNCTION TEST; LIVER METABOLISM; MALE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PLASMA PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 0029869420     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04190.x     Document Type: Article

References (22)

1. Cunningham D, Hawthorn J, Pople A: Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist. Lancet 1987;1:1461-1462.
2. Priestman TJ: Clinical studies with ondansetron in the control of radiation-induced emesis. Eur J Cancer Oncol 1989;25(suppl 1): S29-S33.
3. Leeser J, Lip H: Prevention of postoperative nausea and vomiting using ondansetron, a new selective, 5-HT3 receptor antagonist. Anesth Analg 1992;72:751-755.
4. Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL: Efficacy of ondansetron (GR38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 1990;322:810-816.
5. Figg VVD, Graham CL, Hak LJ, Dukes GE: Ondansetron: a novel antiemetic agent. South Med J 1993;86:497-502.
6. Smith RN: Safety of ondansetron. Eur J Cancer Clin Oncol 1991;25(suppl 1):S47-S50.
7. Colthap PV, Palmer JL: The determination in plasma and pharmacokinetics of ondansetron. Eur J Cancer Clin Oncol 1989; 25(suppl 1):S71-S74.
8. Blackwell LP, Harding SM: The clinical pharmacology of ondansetron. Eur J Cancer Clin Oncol 1989;25(suppl 1):S21-S24.
9. Pritchard JF, Bryson JC, Kernodle AE, Benedetti TL, Powell JR: Age and gender effect on ondansetron pharmacokinetics: Evaluation of healthy volunteers. Clin Pharmacol Ther 1992;51:51-54.
10. Saynor DA, Dixon CM: The metabolism of ondansetron. Eur J Cancer Clin Oncol 1989;25(suppl 1):S75-S77.
11. Dixon CM, Colthup PV, Serabjit-Singh CJ, Kerr BM, Boehlert CC, Park GR, Tarbit MH: Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 1995;23:1225-1230.
12. Ashforth EIL, Palmer JL, Bye A. Bedding A: The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine. Br J Clin Pharmacol 1994;37:389-391.
13. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-649.
14. Reemtsma K, Hottinger GC, DeGraff AC, et al: The estimation of hepatic blood flow using indocyanine green. Surg Gynecol Obstet 1960;110:353-356.
15. Andreasen PB, Ranek L, Statland BE, Tygstrup N: Clearance of antipyrine-dependence of quantitative liver function. Eur J Clin Invest 1974;4:129-134.
16. Donn KH, Powell JR, Rogers JF, Plachetka JR: Lack of effect of histamine H2-receptro antagonist on indocyanine green disposition measured by two methods. J Clin Pharmacol 1984;24:360-370.
17. Danhof M, de Groot-van Vis E, Breimer DD: Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man. Pharmacology 1979;18:210-223.
18. Yamaoka K, Nakagawa J, Uno T: Application of Akaike's information criterion in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;2:165-175.
19. Figg WD, Dukes GE, Lesesne HR, Carson SW, Songer SS, Pritchard JF, et al: Comparison of quantitative methods to assess hepatic function: Pugh's classification, indocyanine green, antipyrine, and dextromethorphan. Pharmacotherapy 1995;15:693-700.
20. Wilkinson GR, Shand DG: A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975;18:377-390.
21. Kornhauser DM, Wood AJJ, Vestal RE, Wilkinson GR, Branch RA, Shand DG: Biological determinants of propranolol disposition in man. Clin Pharmacol Ther 1978;23:165-174.
22. Haberer LJ, Gooding AE, Yin Y, Donn KH: A dose-proportionality study of ondansetron administered as a single oral dose (tablet) to healthy male volunteers (abstract). Pharm Res 1993; 10(Suppl):S333.